Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 16/20 | 0.42 |
| ▸ | HRH1 | P35367 | 15/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335008 | 1.00 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CCR3HRH1 | |
| Hydrochloric Acid SCHEMBL5339666 | 0.99 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CCR3HRH1 | |
| Hydrochloric Acid SCHEMBL5339660 | 0.99 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CCR3HRH1 | |
| SCHEMBL5333037 | 0.89 | KMT2A (0.41) | CCR3HRH1MEN1KMT2AKDM4E | |
| SCHEMBL5333029 | 0.89 | KMT2A (0.41) | CCR3HRH1MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL5337850 | 0.88 | FPR2 (0.39) | CCR3HRH1FPR2PROKR1 | |
| Hydrochloric Acid SCHEMBL5338595 | 0.88 | KMT2A (0.40) | CCR3HRH1MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL5337841 | 0.88 | FPR2 (0.39) | CCR3HRH1FPR2PROKR1 | |
| Hydrochloric Acid SCHEMBL5338587 | 0.88 | KMT2A (0.40) | CCR3HRH1MEN1KMT2AKDM4E | |
| SCHEMBL5331649 | 0.85 | SIGMAR1 (0.38) | SLC6A2SLC6A4SLC6A3CCR3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | CCR3, CCR1, CCR9 | SLC6A2 1453/4885SLC6A4 1121/4885SLC6A3 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.